Radiation and resolve: unlocking the synergistic potential of radioimmunotherapy in advanced lung cancer management.

IF 2.3 4区 医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-06 DOI:10.2217/imt-2023-0268
Yi Zhang, Zheng Li, Bingwen Zou
{"title":"Radiation and resolve: unlocking the synergistic potential of radioimmunotherapy in advanced lung cancer management.","authors":"Yi Zhang, Zheng Li, Bingwen Zou","doi":"10.2217/imt-2023-0268","DOIUrl":null,"url":null,"abstract":"<p><p>Plain language summary This editorial talks about combining radiation therapy (using high-energy rays to kill cancer cells) and immunotherapy (boosting the body's immune system to fight cancer) to treat advanced lung cancer. When used together, these therapies can work better to kill more cancer cells and help patients live longer. But, there's still a lot we don't know. For instance, we need to figure out the best timing and doses for these treatments, and which patients will benefit the most. The article stresses that more research is needed to answer these questions and make this combined treatment a more effective option for advanced lung cancer patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"55-58"},"PeriodicalIF":2.3000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/imt-2023-0268","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Plain language summary This editorial talks about combining radiation therapy (using high-energy rays to kill cancer cells) and immunotherapy (boosting the body's immune system to fight cancer) to treat advanced lung cancer. When used together, these therapies can work better to kill more cancer cells and help patients live longer. But, there's still a lot we don't know. For instance, we need to figure out the best timing and doses for these treatments, and which patients will benefit the most. The article stresses that more research is needed to answer these questions and make this combined treatment a more effective option for advanced lung cancer patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
放射与决心:释放放射免疫疗法在晚期肺癌治疗中的协同潜力。
这篇社论谈到了结合放射疗法(使用高能射线杀死癌细胞)和免疫疗法(增强人体免疫系统来对抗癌症)来治疗晚期肺癌。当这些疗法一起使用时,可以更好地杀死更多的癌细胞,帮助患者延长寿命。但是,还有很多我们不知道的。例如,我们需要找出这些治疗的最佳时机和剂量,以及哪些患者将受益最大。文章强调,需要更多的研究来回答这些问题,并使这种联合治疗成为晚期肺癌患者更有效的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
期刊最新文献
Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report. All models are wrong, but are some useful? Toward clinically tractable prediction of immunotherapy response in cancer. Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis. Addressing social and economic disparities in triple-negative breast cancer immunotherapy: a U.S.-focused review. Evaluating inebilizumab in the treatment of generalized myasthenia gravis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1